Skip to content
Bamboo WorksBamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

BGI Genomics

The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe instead.

U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family

The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…
May 30, 2024
2269.HK 2359.HK 2268.HK

New Horizon Health Gets Booster with New Product Approval

Company says its UU Tube used to self-screen for stomach cancer has been approved by China’s health regulator Key takeaways: New Horizon Health says its first-of-its-kind UU Tube self-screening product…
January 12, 2022

Recent Articles

The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe instead.
May 30, 2024

U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family

2269.HK 2359.HK 2268.HK
January 12, 2022

New Horizon Health Gets Booster with New Product Approval

RECENT ARTICLES

  1. WuXi Biologics
    January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  2. January 27, 2025
    A Drug Company’s Forced Sales, and a Family Feud in Shanghai
    2269.HK 2359.HK
  3. December 27, 2024
    BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
    2359.HK 603259.SHG
  4. December 12, 2024
    Xiaocaiyuan sets the table for Hong Kong IPO. But is the timing right?
    0999.HK
  5. March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.